2011-12-08-世界卫生组织-INN_Proposed_List_106_53页_497kb

Summary of Proposed INN (List 106) for WHO Drug Information Vol. 25, No. 4, 2011

Purpose

• This document outlines the Proposed International Nonproprietary Names (Proposed INN or DCI Proposée/DCI Propuesta) for pharmaceutical substances, as listed in List 106, published in WHO Drug Information Volume 25, Issue 4, January 2011.
• The selection procedure, INN development principles, submission procedures, comments/objections, and the timeline for adopting Recommended INNs are detailed in the Annexes.
• Proposed INNs are provisional and open for public comments or formal objections within four months from the publication date (31 May 2012 for List 106).

Key Details

• Publication Date: 31 January 2011.
• Objection Deadline: 31 May 2012.
• INN Programme: Ongoing according to finalized rules.

Proposed INNs Summary (Listed for the First 30 entries due to length)

1. acidum deoxycholicum / deoxycholic acid (Endogenous Bile Salt) - Used cautiously in surgical procedures.
2. acidum florilglutamicum (18F) / florilglutamic acid (18F) (Diagnostic Aid for PET imaging).
3. acidum tiazoticum / tiazotic acid (Antioxidant).
4. amitifadinum / amitifadine (Antidepressant).
5. bamosiranum (siRNA inhibitor) (Antiglaucoma).
6. brexpiprazolum / brexpiprazole (Antipsychotic).
7. buparlisibum / buparlisib (Antineoplastic).
8. camicinalum / camicinal (Digestive Agent).
9. caplacizumabum / caplacizumab (Antithrombotic).
10. cerlapirdinum / cerlapirdine (Serotonin Receptor Antagonist).
11. dexmecamylaminum / dexmecamylamine (Antidepressant).
12. drisapersenum / drisapersen (Myopathy of Duchenne Treatment).
13. faldaprevirum / faldaprevir (Antiviral).
14. flanvotumabum / flanvotumab (Antineoplastic).
15. follitropinum gamma / follitropin gamma (Hormone, Fertility Stimulation).
16. gemcitabini elaidas / gemcitabine elaidate (Antineoplastic).
17. glyceroli phenylbutras / glycerol phenylbutyrate (Urea Cycle Disorders).
18. idursulfasum beta / idursulfase beta (Enzyme, Mucopolysaccharidoses Treatment).
19. inclacumabum / inclacumab (Antithrombotic).
20. lucerastatum / lucerastat (Ceramide Glucosyltransferase Inhibitor).

Process Notes

• Comments/Objections: Any person can submit comments or formal objections within four months.
• Validity: Proposed INNs are provisional and may evolve or be adopted (Recommended INN) based on feedback.
• See the full list (106 items) in the publication for complete details including chemical names, structures, actions, and uses.